Aardvark Therapeutics (AARD) vs Corbus Pharmaceuticals (CRBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Corbus Pharmaceuticals (CRBP) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 60.7% versus a loss of 72.5%. Corbus Pharmaceuticals is the larger company by market cap ($106.2 million vs $104.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | CRBP |
|---|---|---|
| Share price | $4.75 | $5.49 |
| Market cap | $103.95M | $106.18M |
| 1-day change | +0.85% | +4.17% |
| YTD return | -64.11% | -35.26% |
| 1-year return | -72.50% | -60.73% |
| 5-year return | — | -82.78% |
| EPS (TTM) | $-3.21 | $-6.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $20.56 |
| 52-week low | $3.35 | $5.13 |
| Distance from 52-week high | -72.15% | -73.30% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +133.89% | +519.85% |
| Average volume | 208.11K | 756.54K |
| Shares outstanding | 21.88M | 19.34M |
| Employees | 28 | 36 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRBP has outperformed AARD by 11.8 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees
AARD vs CRBP FAQ
Which is bigger, Aardvark Therapeutics or Corbus Pharmaceuticals?
Corbus Pharmaceuticals (CRBP) is larger, with a market capitalization of $106.18M compared with $103.95M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or CRBP?
CRBP returned -60.73% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Corbus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.